AI assistant
Camlin Fine Sciences Ltd — Investor Presentation 2019
May 27, 2019
59255_rns_2019-05-27_6098c03c-01f7-482c-a2c5-b75da0da827c.pdf
Investor Presentation
Open in viewerOpens in your device viewer
Date: 25/05/2019
==> picture [123 x 38] intentionally omitted <==
||To,
BSE Limited,
25, P. J. Towers,
Dalal Street,
Mumbai – 400 001
Ref:Company Scrip Code: 532834|To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400051
Ref:Symbol:CAMLINFINE||Series: EQ|
|---|---|---|
Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - (“SEBI LODR”)
This is in continuation to our disclosure dated May 23, 2019 in relation to the conference call with various domestic and international investors and analysts to discuss the financial results of the Company for the quarter ended March 31, 2019 (Q4) on May 27, 2019, please find enclosed herewith the investor presentation made for the aforesaid call.
It is clarified that the presentation and the information contained therein does not constitute or form part of an invitation or solicitation to offer to purchase or subscribe to any securities of the Company in any jurisdiction. This presentation has been prepared for information purposes only. The information contained in the investor presentation is not to be taken as any recommendation made by the Company or any other person to enter into any agreement with regard to any investment.
We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI LODR.
Thanking You, Encl.: a/a. For Camlin Fine Sciences Limited
==> picture [220 x 66] intentionally omitted <==
==> picture [477 x 71] intentionally omitted <==
EARNINGS PRESENTATION Q4-‐FY19
/
FY19
2 Executive
Summary
**Company
Overview**
==> picture [164 x 122] intentionally omitted <==
-
Camlin Fine Sciences Limited (CFS), formed in 2006 after demerging the fine chemical business from Camlin Ltd., is a vertically integrated company engaged in research, development, manufacturing, commercializing and marketing of specialty chemicals and blends, which are used in a wide array of sectors.
-
CFS is global leading producer of food antioxidants, such as TBHQ & BHA, and the world’s 3[rd] largest producer of Vanillin.
**FY19
Business
Mix
(Revenue
Share
%)**
-
Shelf
Life
Solutions
(54%)
:
Includes
Anti-‐oxidants,
Blends
and
Additives -
Performance
Chemicals
(27%):
Includes
Specialty
Chemicals -
Aroma
Chemicals
(17%):
Includes
Vanillin
and
Ethyl
Vanillin
**Manufacturing
Facilities,
R&D
Centres and
Application
Labs**
==> picture [69 x 30] intentionally omitted <==
**Financials
FY19
(INR
Mn)**
==> picture [39 x 8] intentionally omitted <==
----- Start of picture text -----
Revenue
----- End of picture text -----
8,922
EBITDA 693[*]
==> picture [45 x 13] intentionally omitted <==
----- Start of picture text -----
Net
Worth
----- End of picture text -----
4,308[#]
Manufacturing
Facilities
in India,
Brazil,
China, Mexico
and
Italy
R&D
Centres at Tarapur(India)
and Ravenna
(Italy)
Application
Labs
in
India, Brazil,
North
America, Italy
and
Mexico
* Excluding Other Income &Foreign Exchange Fluctuation Gain/ (Loss) #Including
non
controlling
interest
Snapshot
==> picture [81 x 62] intentionally omitted <==
One
of
the
few vertically
and backward integrated
players
==> picture [58 x 59] intentionally omitted <==
Serving
more
than
80 countries
with
over 100
products
5 Manufacturing Facilities,
2
R&D Centres
and
5 Application
Labs
==> picture [72 x 58] intentionally omitted <==
==> picture [72 x 60] intentionally omitted <==
Leading
Manufacturers
of Antioxidants
in
the
world with
more
than
30
years
of experience
==> picture [59 x 58] intentionally omitted <==
Preferred
Partner
for manufacturing
customized products
==> picture [70 x 57] intentionally omitted <==
Global
expertise,
local
solutions
==> picture [75 x 61] intentionally omitted <==
==> picture [82 x 70] intentionally omitted <==
==> picture [58 x 58] intentionally omitted <==
==> picture [69 x 30] intentionally omitted <==
3[rd] largest
producer
of Vanillin
in
the
world
Strategic
move
to
start blends
which
have
higher margins
Strong
management team
with
experienced industry
professionals
About
the
Company
-
In 2006, Camlin Fine Sciences Limited (CFS) was formed after de-‐merging (mirror shareholding) the fine chemical business from Camlin Ltd.
- 10,000
-
The Company has over 30 years of experience providing innovative solutions with a competitive advantage in fine sciences.
-
CFS is a vertically integrated company, engaged in research, development, manufacturing, commercializing and marketing of specialty chemicals and blends, which are used in a wide array of sectors.
-
Food, feed, animal and pet nutrition
oPetro chemicals -
Flavours & Fragrance
-
Dyes and Pigments
-
Pharma
- Polymers
-
Agro Chemicals
oBio Diesel -
CFS categorizes their business into 3 different verticals based on their product portfolio, namely: Shelf-‐Life Solutions (which include anti-‐oxidants, its blends and additives), Performance chemicals and Aroma Chemicals.
-
CFS has subsidiaries in Mexico, North America, China, Europe and Brazil serving in more than 80 countries with more than 100 products and over 1,000 satisfied customers.
-
CFS markets its products in Europe, Asia Pacific (including India), North Africa, Middle East, South, Central and North America.
==> picture [69 x 30] intentionally omitted <==
**Total
Operational
Revenue
(INR
Mn)**
==> picture [182 x 117] intentionally omitted <==
----- Start of picture text -----
8,992
7,228
5,667
5,469
5,042
FY15 FY16 FY17 FY18 FY19
----- End of picture text -----
FY19
Operational
Revenue
Breakup
==> picture [131 x 137] intentionally omitted <==
----- Start of picture text -----
Others,
2%
Aroma Performance
17%
Chemicals
27%
Shelf-‐life
Extension
25% Blends 29%
----- End of picture text -----
**Q4-‐FY19
/
FY19
FINANCIAL
OVERVIEW**
6
Q4-‐FY19
Standalone
Income
Statement
(Ind-‐AS)
==> picture [69 x 30] intentionally omitted <==
| Income Statement (Mn) | Q4-FY19 | Q4-FY18 | Y-o-Y | Q3-FY19 | Q-o-Q |
|---|---|---|---|---|---|
| Operational Revenue | 1,715 | 1,282 | 33.8% | 1,499 | 14.4% |
| Total Expenses | 1,629 | 1,171 | 39.1% | 1,576 | 3.4% |
| Operational EBITDA* | 123 | 111 | 10.8% | 28 | 339% |
| Operational EBITDA Margins (%) | 7.19% | 8.64% | (145) Bps | 1.84% | NA |
| EBITDA | 86 | 111 | (22.5)% | (77) | 535 Bps |
| EBITDA Margins(%) | 5.01% | 8.64% | (365) Bps | - | NA |
| Other Income | 18 | 52 | (65.4)% | 14 | (28.6)% |
| Depreciation | 22 | 22 | - | 23 | (4.3)% |
| Finance Cost | 52 | 62 | (16.1)% | 16 | 225.0% |
| PBT | 30 | 79 | (62.0)% | (102) | NA |
| Tax | 3 | 67 | (95.5)% | (49) | NA |
| Profit After tax | 27 | 12 | 125.0% | (53) | NA |
| PAT Margins (%) | 1.56% | 0.90% | 66 Bps | - | NA |
| Other Comprehensive Income | 1 | 3 | (66.7)% | (3) | NA |
| Total Comprehensive Income | 28 | 15 | 86.7% | (56) | NA |
| Diluted EPS (INR) | 0.22 | (0.26) | NA | (0.44) | NA |
* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)
7
FY19
Standalone
Income
Statement
(Ind-‐AS)
==> picture [69 x 30] intentionally omitted <==
| Particulars (INR Mn) | FY19 | FY18 | Y-o-Y |
|---|---|---|---|
| Operational Revenue | 5,481 | 4,050 | 35.3% |
| Total Expenses | 5,153 | 3,996 | 28.9% |
| Operational EBITDA* | 328 | 54 | NA |
| Operational EBITDA Margins (%) | 5.98% | 1.33% | 465 Bps |
| Other Income | 108 | 92 | (17.4)% |
| Depreciation | 91 | 91 | - |
| Finance Cost | 203 | 236 | (14.0)% |
| Exceptional Items | - | - | - |
| PBT | 142 | (181) | NA |
| Tax | 35 | (39) | NA |
| Profit After Tax | 107 | (142) | NA |
| PAT Margin | 1.91% | - | NA |
| Other Comprehensive Income | (3) | 1 | NA |
| Total Comprehensive Income | 104 | (141) | NA |
| Diluted EPS (INR per share) | 0.88 | (1.63) | NA |
* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)
8
Q4-‐FY19
Consolidated
Income
Statement
(Ind-‐AS)
==> picture [69 x 30] intentionally omitted <==
| Income Statement (INR Mn) | Q4-FY19 | Q4-FY18 | Y-o-Y | Q3-FY19 | Q-o-Q |
|---|---|---|---|---|---|
| Operational Revenue | 2,680 | 2,317 | 15.7% | 2,414 | 11.0% |
| Total Expenses | 2,512 | 2,213 | 13.5% | 2,260 | 11.2% |
| Operational EBITDA* | 214 | 106 | 102% | 208 | 2.9% |
| Operational EBITDA Margins (%) | 7.97% | 4.58% | 339 Bps | 8.60% | (63) Bps |
| EBITDA | 168 | 104 | 61.5% | 154 | 9.1% |
| EBITDA Margins (%) | 6.27% | 4.49% | 178 Bps | 6.38% | (11) Bps |
| Other Income | 46 | 87 | (47.1)% | 8 | 475.0% |
| Depreciation | 73 | 98 | (25.5)% | 68 | 7.4% |
| Finance Cost | 73 | 42 | 73.8% | 110 | (33.6)% |
| Share of profit/ loss of associate | (1) | 2 | NA | - | NA |
| PBT | 67 | 53 | 26.4% | (16) | NA |
| Tax | 4 | 96 | NA | (8) | NA |
| Profit After Tax | 63 | (43) | NA | (8) | NA |
| PAT Margins (%) | 2.35% | - | NA | - | NA |
| Other Comprehensive Income | 31 | 60 | (48.3)% | (44) | NA |
| Total Comprehensive Income | 94 | 17 | NA | (52) | NA |
| Diluted EPS (INR) | 0.60 | (0.64) | NA | (0.17) | NA |
* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)
FY19
Consolidated
Income
Statement
(Ind-‐AS)
9
==> picture [69 x 30] intentionally omitted <==
| Income Statement(INR Mn) | FY19 | FY18 | Y-o-Y |
|---|---|---|---|
| Operational Revenue | 8,922 | 7,228 | 23.4% |
| Total Expenses | 8,235 | 7,073 | 16.4% |
| Operational EBITDA* | 693 | 156 | NA |
| Operational EBITDA Margins (%) | 7.77% | 2.16% | 561 Bps |
| EBITDA | 687 | 155 | 343.2% |
| EBITDA Margins (%) | 7.70% | 2.14% | 556 Bps |
| Other Income | 138 | 86 | 60.5% |
| Depreciation | 290 | 267 | 8.6% |
| Finance Cost | 367 | 284 | 29.2% |
| Share of profit/ loss of associate | (1) | 2 | NA |
| PBT | 167 | (308) | NA |
| Tax | 137 | (68) | NA |
| Profit After Tax | 30 | (240) | NA |
| PAT Margins (%) | 0.33% | - | NA |
| Other Comprehensive Income | 5 | 124 | NA |
| Total Comprehensive Income | 35 | (116) | NA |
| Diluted EPS (INR) | 0.05 | (3.01) | NA |
* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)
==> picture [69 x 30] intentionally omitted <==
**COUNTRY
OVERVIEW**
CFS
India
-
R&D Centre at Tarapur that has developed many new Diphenol-‐downstream products
-
Shelf Life Solutions Development, Testing and Applications Lab at Mumbai that works on testing food formulations and blends for the food, pet food and animal nutrition industries
-
Provides technical expertise and support for shelf life solutions and aroma ingredients to the various laboratories of CFS located globally
Manufacturing Capacity
/
Year Manufacturing Total (PC) Capacity
/
Year Employee
Strength Increased
from (Anti-‐oxidant
Ingredients) 6,000
MT
to 5,000
MT 350+ 10,000
MT
==> picture [267 x 105] intentionally omitted <==
----- Start of picture text -----
Operational
Revenue
(INR
Mn)
5,481
6,000
4,227
4,050
3,376
4,000
2,000
-‐
FY16 FY17 FY18 FY19
----- End of picture text -----
==> picture [69 x 30] intentionally omitted <==
==> picture [178 x 142] intentionally omitted <==
----- Start of picture text -----
Tarapur
Khopoli Mahad
Mumbai
----- End of picture text -----
Owned
Plant Marketing
offices R&D/
Food
Labs Outsourced
Manufacturing
Facilities Blending
Facility
**Quarterly
Operational
Revenue
(INR
Mn)**
==> picture [259 x 90] intentionally omitted <==
----- Start of picture text -----
2,000
1,715
1,499
1,282
1,000
-‐
Q4-‐FY18 Q3-‐FY19 Q4-‐FY19
----- End of picture text -----
Update
on
Dahej Project
==> picture [69 x 30] intentionally omitted <==
**Work
/
Activities
completed**
-
Financial Closing achieved
-
Basic Process & Mechanical Equipment Engineering
-
Long lead equipment (process & utility) as well as major equipments – Orders received except Boiler
-
Civil / Structural Engineering for major non-‐process buildings, compound hall, Warehouse
-
Civil Contractors / Engineering Head / Third Party Inspection Agency / Construction Management Company appointed
Time
line
-
Office staff / Production head / Instrumentation head / Security Agency appointed
-
Water & Electricity connections in place & HAZOP study done
-
Detailed process Engineering -‐ Electricals
-
Engineering of Piping, Instrumentation & Controls
-
Civil work of internal roads & area grading
==> picture [128 x 53] intentionally omitted <==
----- Start of picture text -----
Trials,
commissioning
by
the
end
of
Q2-‐FY20
----- End of picture text -----
**Work
in
progress**
-
Construction of Plant Building, Cooling Towers, storage tanks, admin building, pipe racks in progress
-
Piping work in progress
-
Pre-‐construction activity of Solvent Area, Tank Farms, Substations, etc.
13
CFS
Mexico
==> picture [69 x 30] intentionally omitted <==
==> picture [321 x 330] intentionally omitted <==
----- Start of picture text -----
Cuba
Mexico
city
Republic
of
of
Guatemala Dominica
Colombia
Peru
Owned
Plant Marketing
offices
Blending
Facility
Quarterly
Operational
Revenue
(INR
Mn)
800
581
520
600
391
400
200
-‐
Q4-‐FY18 Q3-‐FY19 Q4-‐FY19
----- End of picture text -----
-
Acquire 65% stake in Dresen Quimica SAPI De CV, Mexico in May 2016
-
Primarily manufactures Blends and Additives
-
Key customer segments: Oil, Poultry, Diary, Rendering, Aqua, Pet food, Swine, Vitamin Pre-‐mix
-
Total Market size is ~USD 200 Mn and CFS Mexico enjoys an overall market share of ~15% giving enough growth opportunities
==> picture [93 x 49] intentionally omitted <==
----- Start of picture text -----
Total
Employee
Strength
130+
----- End of picture text -----
Manufacturing Capacity
/
Year 12,000
MT
**Operational
Revenue
(INR
Mn)**
==> picture [244 x 92] intentionally omitted <==
----- Start of picture text -----
3,000
2,172
1,642
2,000
1,210
1,000
-‐
FY17 FY18 FY19
----- End of picture text -----
14
CFS
Europe
==> picture [69 x 30] intentionally omitted <==
Performance Chemicals
-
Acquired the manufacturing facility at Ravenna, Italy in 2011, which provides captive requirements of key raw materials i.e. Hydroquinone and Catechol
-
Capacity utilization achieved at 95% in FY19
-
Considerable growth in EBITDA Margins & Profits due to favourable prices and better yields
Total Employee
Strength 50+
Manufacturing Capacity
/
Year 12,000
MT
Shelf Life Solutions
-
Application lab commenced in October 2018
-
The Blending plant was commissioned in March 2019
-
Dedicated Sales team being appointed to cover the entire European market
-
On-‐boarded 5 customers
==> picture [241 x 227] intentionally omitted <==
----- Start of picture text -----
Ravenna,
Italy
Owned
Plant Marketing
offices R&D/
Food
Labs
----- End of picture text -----
**Operational
Revenue
(INR
Mn)**
==> picture [267 x 90] intentionally omitted <==
----- Start of picture text -----
4,000
3,290
2,771
2,258
2,216
2,000
-‐
FY16 FY17 FY18 FY19
----- End of picture text -----
==> picture [238 x 18] intentionally omitted <==
----- Start of picture text -----
Quarterly
Operational
Revenue
(INR
Mn)
----- End of picture text -----
==> picture [259 x 91] intentionally omitted <==
----- Start of picture text -----
1,000
841
857
872
500
-‐
Q4-‐FY18 Q3-‐FY19 Q4-‐FY19
----- End of picture text -----
15
CFS
Brazil
==> picture [69 x 30] intentionally omitted <==
Shelf Life Solutions
-
Formed in 2013 for Blends and the production started in 2015
-
Has an application lab in Indaiatuba – Brazil for customizing blends for Shelf-‐life Extension Solutions.
-
Handles distribution of bulk antioxidants and vanillin.
-
Key customer segments: Oil, Poultry, Diary, Rendering, Aqua, Pet food, Swine, Vitamin Pre-‐mix and Bio Diesel
-
Dedicated facility for animal feed and pet food additives.
-
Revenue will continue to grow due to launch of new products in animal nutrition and better penetration of markets
Manufacturing Capacity
/
Year 6,000
MT
Total Employee
Strength 30+
==> picture [183 x 161] intentionally omitted <==
----- Start of picture text -----
Indaiatuba,
Brazil
Chile
Argentina
----- End of picture text -----
Marketing
offices R&D/
Food
Labs Outsourced
Manufacturing
Facilities Blending
Facility
Operational
Revenue
(INR
Mn)
==> picture [257 x 85] intentionally omitted <==
----- Start of picture text -----
600
411
400
252
222
172
200
-‐
FY16 FY17 FY18 FY19
----- End of picture text -----
**Quarterly
Operational
Revenue
(INR
Mn)**
==> picture [251 x 87] intentionally omitted <==
----- Start of picture text -----
150
108
91
100
60
50
-‐
Q4-‐FY18 Q3-‐FY19 Q4-‐FY19
----- End of picture text -----
16
CFS
Wanglong
==> picture [69 x 30] intentionally omitted <==
-
CFS along with CFS Europe acquired 51% stake in Ningbo Wanglong Flavours in 2017 which had an operational plant since 2011
-
This acquisition makes CFS the 3[rd] largest producer of Vanillin
-
Located in Grade 1 Industrial zone in the city of Yuyao Zhejiang Province, China.
-
It manufactures Vanillin through a dedicated manufacturing facility which started at the end of Q2-‐FY18
-
With capacity expansion of Guaiacol in India, we are covered for 100% of primary raw material
-
Establishing a distribution network across the globe
==> picture [300 x 176] intentionally omitted <==
----- Start of picture text -----
Yuyao Zhejaing
Province,
China
Owned
Plant Marketing
offices Wanglong
----- End of picture text -----
==> picture [135 x 101] intentionally omitted <==
----- Start of picture text -----
Manufacturing
Capacity
/
Year
4,200
MT
----- End of picture text -----
==> picture [136 x 101] intentionally omitted <==
----- Start of picture text -----
Capacity
utilization
~55%
----- End of picture text -----
**Quarterly
Operational
Revenue
(INR
Mn)**
==> picture [394 x 104] intentionally omitted <==
----- Start of picture text -----
1,000
Total
629
555
Employee
Strength
500
310
75+
-‐
Q4-‐FY18 Q3-‐FY19 Q4-‐FY19
----- End of picture text -----
17
CFS
North
America
Shelf Life Solutions
- Formed in October 2015 as a wholly owned subsidiary
Market focus
-
Food -‐ Bulk oils (synthetic antioxidants), Meat & poultry (natural antioxidants)
-
Pet food -‐ Rendering for pet food (natural antioxidants), Rendering for animal feed (synthetic antioxidants)
-
Animal feed – Antioxidants, Mould Inhibitors, Gut Health Probiotics, Others
-
Has launched new products in natural anti-‐oxidants and animal nutrition
-
Built a strong diversified portfolio of 40+ products
Total
Number
of
Customers 6+
Total
Employee
Strength 10+
**Operational
Revenue
(INR
Mn)**
==> picture [257 x 85] intentionally omitted <==
----- Start of picture text -----
300
236
178
200
109
100
12
-‐
FY16 FY17 FY18 FY19
----- End of picture text -----
==> picture [69 x 30] intentionally omitted <==
==> picture [300 x 200] intentionally omitted <==
----- Start of picture text -----
Iowa,
USA
Marketing
offices R&D/
Food
Labs
Outsourced
Manufacturing
Facilities
----- End of picture text -----
==> picture [257 x 107] intentionally omitted <==
----- Start of picture text -----
Quarterly
Operational
Revenue
(INR
Mn)
150
128
100
52
32
50
-‐
Q4-‐FY18 Q3-‐FY19 Q4-‐FY19
----- End of picture text -----
**HISTORICAL
FINANCIAL
OVERVIEW**
19
Standalone
Income
Statement
==> picture [69 x 30] intentionally omitted <==
| Particulars (INR Mn) | FY16 | FY17* | FY18* | FY19* |
|---|---|---|---|---|
| Operational Income | 4,227 | 3,376 | 4,050 | 5,481 |
| Total Expenses | 3,553 | 3,156 | 3,996 | 5,153 |
| EBITDA | 674 | 220 | 54 | 328 |
| EBITDA Margin | 15.94% | 6.52% | 1.33% | 5.98% |
| Depreciation | 101 | 116 | 91 | 91 |
| Finance Cost | 218 | 232 | 236 | 203 |
| Other Income | 37 | 129 | 92 | 108 |
| Exceptional Items | 45 | - | - | - |
| PBT | 347 | 1 | (181) | 142 |
| Tax | 90 | 9 | (39) | 35 |
| Profit After Tax | 257 | (8) | (142) | 107 |
| PAT Margin | 6.03% | NA | NA | 1.91% |
| Other Comprehensive Income | - | (1) | 1 | (3) |
| Total Comprehensive Income | 257 | (9) | (141) | 104 |
| Diluted EPS (INR per share) | 2.67 | (0.23) | (1.63) | 0.88 |
*As
per
IND-‐AS
20
Standalone
Balance
Sheet
(IND-‐As)
==> picture [69 x 30] intentionally omitted <==
| Particulars(INR Mn) | FY18 | FY19 | Particulars(INR Mn) | FY18 | FY19 |
|---|---|---|---|---|---|
| EQUITY | 3,314 | 3,474 | Non-Current Assets | 1,597 | 2,735 |
| a)EquityShare Capital | 121 | 121 | a)Property,Plant and Equipment |
683 | 789 |
b)Other Equity |
3,193 | 3,353 | b)Capital Work In Progress |
120 | 524 |
c)Non-ControllingInterest |
- | c)Investment Property |
21 | 21 | |
e)Other Intangible Assets |
12 | 7 | |||
| LIABILITIES | 182 | 1,166 | f)Intangible Assets under Development |
78 | 161 |
| Non-Current Liabilities | h)Financial Assets |
||||
Financial Liabilities |
(i)Investments |
400 | 657 | ||
a)Borrowings |
145 | 1,111 | (ii)Loans |
190 | 288 |
b)Provisions |
20 | 24 | (iii)Other Financial Assets |
||
c)Deferred Tax Liabilities(Net) |
i)Deferred tax assets(Net) |
17 | 12 | ||
d)Other Non-Current Liabilities |
17 | 31 | j)Income Tax Assets |
28 | 36 |
k)Other Non-Current assets |
48 | 240 | |||
| Current Liabilities | 3,282 | 3,170 | Current Assets |
5,181 | 5,075 |
a)Financial Liabilities |
a)Inventories |
1,148 | 1,093 | ||
(i)Borrowings |
2,003 | 1,990 | b)Financial Assets |
||
(ii)Trade Payables |
1,142 | 1,059 | (i)Investments |
1,081 | 33 |
(iii)Other Financial Liabilities |
97 | 98 | (ii)Trade Receivables |
2,114 | 2,619 |
b)Other Current Liabilities |
33 | 15 | (iii)Cash and Cash Equivalents |
18 | 189 |
c)Provisions |
4 | 3 | (iv)Other Bank balances |
96 | 502 |
d)Current Tax Liabilities(Net) |
3 | 5 | (v)Loans |
234 | 161 |
(vi)Other financial assets |
192 | 221 | |||
c)Other Current Assets |
298 | 257 | |||
d)Asset held for Sale |
|||||
| GRAND TOTAL - EQUITIES & LIABILITES | 6,778 | 7,810 | GRAND TOTAL – ASSETS |
6,778 | 7,810 |
21
Consolidated
Income
Statement
==> picture [69 x 30] intentionally omitted <==
| PARTICULARS (INR Mn) | FY16 | FY17* | FY18* | FY19* |
|---|---|---|---|---|
| Operational Income | 5,042 | 5,469 | 7,228 | 8,922 |
| Total Expenses | 4,125 | 5,187 | 7,073 | 8,235 |
| EBITDA | 917 | 282 | 155 | 687 |
| EBITDA Margin | 18.19% | 5.16% | 2.14% | 7.70% |
| Depreciation | 171 | 218 | 267 | 290 |
| Finance Cost | 244 | 269 | 284 | 367 |
| Other Income | 43 | 145 | 86 | 138 |
| Exceptional Items | (45) | - | - | - |
| Income from Associate | - | - | 2 | (1) |
| PBT | 500 | (60) | (308) | 167 |
| Tax | 142 | 16 | (68) | 137 |
| Profit After Tax | 358 | (44) | (240) | 30 |
| PAT Margin | 7.04% | NA | - | 0.33% |
| Other Comprehensive Income | - | (55) | 124 | 5 |
| Total Comprehensive Income | 358 | (99) | (116) | 35 |
| Diluted EPS (INR per share) | 3.71 | (1.25) | (3.01) | 0.05 |
*As
per
IND-‐AS
22
Consolidated
Balance
Sheet
(IND-‐As)
==> picture [69 x 30] intentionally omitted <==
| PARTICULARS(INR Mn) | FY18 | FY19 | PARTICULARS(INR Mn) |
FY18 | FY19 |
|---|---|---|---|---|---|
| EQUITY |
4,334 | 4,303 | Non-Current Assets |
3,510 | 4,143 |
| a)EquityShare Capital |
121 | 121 | a)Property,Plant and Equipment |
2,066 | 2,086 |
| b)Other Equity |
3,591 | 3,588 | b)Capital Work In Progress |
129 | 536 |
| c)Non-ControllingInterest | 622 | 594 | c)Investment Property |
21 | 21 |
| d)Goodwill |
446 | 444 | |||
| LIABILITIES |
e)Other Intangible Assets |
248 | 174 | ||
| Non-Current Liabilities |
1,122 | 1,891 | f)Intangible Assets under Development |
8 | 54 |
| Financial Liabilities |
g)Investment in Associate |
2 | 2 | ||
| a)Borrowings |
1,102 | 1,849 | h)Financial Assets |
||
| b)Provisions |
20 | 23 | (i)Investments |
71 | 71 |
| c)Deferred Tax Liabilities(Net) |
1 | (ii)Loans |
7 | 111 | |
| d)Other Non-Current Liabilities | - | 18 | (iii)Other Financial Assets |
||
| i)Deferred tax assets(Net) |
396 | 412 | |||
| j)Income Tax Assets |
68 | 74 | |||
| k)Other Non-Current assets |
48 | 158 | |||
| Current Liabilities |
4,709 | 4,674 | Current Assets |
6,655 | 6,725 |
| a)Financial Liabilities |
a)Inventories |
2,390 | 2,854 | ||
| (i)Borrowings |
2,468 | 2,470 | b)Financial Assets |
||
| (ii)Trade Payables |
1,777 | 1,708 | (i)Investments |
1,081 | 33 |
| (iii)Other Financial Liabilities |
306 | 348 | (ii)Trade Receivables |
2,053 | 2,093 |
| b)Other Current Liabilities |
85 | 73 | (iii)Cash and Cash Equivalents |
385 | 532 |
| c)Provisions |
70 | 70 | (iv)Other Bank balances |
96 | 502 |
| d)Current Tax Liabilities(Net) | 3 | 5 | (v)Loans |
34 | 31 |
| (vi)Other financial assets |
62 | 108 | |||
| c)Other Current Assets |
554 | 572 | |||
| d)Asset held for Sale |
|||||
| GRAND TOTAL - EQUITIES & LIABILITES | 10,165 | 10,868 | GRAND TOTAL – ASSETS | 10,165 | 10,868 |
20.00% 15.00%
Consolidated
Financial
Highlights
**Operational
Revenue
(INR
Mn)**
==> picture [281 x 119] intentionally omitted <==
----- Start of picture text -----
10,000
8,922
8,000
7,228
5,469
6,000
5,042
4,000
2,000
-‐
FY16 FY17 FY18 FY19
----- End of picture text -----*
**Net
Debt
to
Equity**
==> picture [264 x 120] intentionally omitted <==
----- Start of picture text -----
1.40
1.5
0.98
0.89
1.0 0.83
0.5
0.0
FY16 FY17 FY18 FY19
----- End of picture text -----*
==> picture [69 x 30] intentionally omitted <==
**EBITDA
(INR
Mn)
&
EBITDA
Margin
(%)**
==> picture [330 x 121] intentionally omitted <==
----- Start of picture text -----
18.19%
1,200
20.00%
900
15.00%
917
600
7.70%687 10.00%
5.16%
300
2.16% 5.00%
282 155
-‐ 0.00%
FY16 FY17 FY18 FY19
----- End of picture text -----*
10.00%
**Net
Worth
(INR
Mn)**
==> picture [276 x 120] intentionally omitted <==
----- Start of picture text -----
4,000
3,712 3,709
3,000
2,126
2,000
1,762
1,000
-‐
FY16 FY17 FY18 FY19
----- End of picture text -----*
*As
per
I-‐GAAP
24
==> picture [153 x 30] intentionally omitted <==
----- Start of picture text -----
24
Capital
Markets
----- End of picture text -----
==> picture [69 x 30] intentionally omitted <==
Share
Price
Data
as
on
31[st
] March,
2019
==> picture [630 x 287] intentionally omitted <==
----- Start of picture text -----
40%
20%
0%
-‐20%
-‐40%
-‐60%
-‐80%
Apr-‐18 May-‐18 Jun-‐18 Jul-‐18 Aug-‐18 Sep-‐18 Oct-‐18 Nov-‐18 Dec-‐18 Jan-‐19 Feb-‐19 Mar-‐19
Camlin Sensex
Price
Data
(31 [st] March,
2019) INR Shareholding
Pattern
as
on
31 [[st]] March,
2019
1.00
Face
Value
49.85 Promoters
Market
Price
FII/Banks
22.55%
1.45%
52
Week
H/L
117.7/
36.7
Public
Market
Cap
(Mn) 6,044.5 DII
57.26%
18.74%
121.25
Equity
Shares
Outstanding
(Mn)
638.76
1
Year
Avg
Trading
Volume
(‘000)
----- End of picture text -----
==> picture [257 x 112] intentionally omitted <==
----- Start of picture text -----
Shareholding
Pattern
as
on
31 [[st]] March,
2019
Promoters
FII/Banks
22.55%
1.45%
Public
DII
57.26%
18.74%
----- End of picture text -----
*
Excluding
Other
Income
25 Disclaimer
==> picture [69 x 30] intentionally omitted <==
Camlin Fine Sciences Limited
No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Camlin Fine Science Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company ’ s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.
Forward-‐looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-‐looking statements, including future changes or developments in the Company ’ s business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-‐looking statements. The Company disclaims any obligation to update these forward-‐looking statements to reflect future events or developments.
This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.
This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.
Valorem Advisors Disclaimer:
Valorem
Advisors
is
an
Independent
Investor
Relations
Management
Service
company.
This
Presentation
has
been
prepared
by
Valorem Advisors
based
on
information
and
data
which
the
Company
considers reliable,
but
Valorem
Advisors
and
the
Company
makes
no
representation
or
warranty,
express
or
implied,
whatsoever,
and
no
reliance
shall
be
placed
on,
the
truth,
accuracy,
completeness,
fairness
and reasonableness
of
the
contents
of
this
Presentation.
This
Presentation
may
not
be
all
inclusive
and
may
not
contain
all
of
the
information
that
you
may
consider
material.
Any
liability
in
respect
of
the
contents
of, or
any
omission
from,
this
Presentation
is
expressly
excluded.
Valorem
Advisors
also
hereby
certifies
that
the
directors
or
employees
of
Valorem
Advisors
do
not
own
any
stock
in
personal
or
company
capacity
of
the
Company
under
review.
==> picture [73 x 60] intentionally omitted <==
For
further
details
please
contact
our
Investor
Relations
Representatives: VALOREM
ADVISORS Mr.
Anuj
Sonpal Tel:
+91-‐22-‐49039500 Email:
[email protected]
26
==> picture [169 x 49] intentionally omitted <==
----- Start of picture text -----
Thank
You
----- End of picture text -----